^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Breast Cancer
    Drug Class:PARP inhibitor +
    EZH2 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    FEBS J
    Title:

    Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer

    Published date:
    02/11/2021
    Excerpt:
    These studies of PARP inhibition combined with EZH2 inhibition in breast cancer showed that this combination may benefit breast cancer patients carrying BRCA1-mutated tumor…
    DOI:
    10.1111/febs.15730